Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the second quarter ended June 30, 2017. Loss from...
July 24, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, July 27, 2017 at 2:00 p.m....
July 18, 2017 16:05 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies

SOUTH SAN FRANCISCO, Calif., July 18, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the first patient has been dosed at the Dana-Farber Institute in the...
June 26, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Added to Russell Microcap® Index

SOUTH SAN FRANCISCO, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it was added to the Russell Microcap® Index when the Russell...
June 23, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from a Washington University-sponsored...
May 08, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the first quarter ended March 31, 2017. Loss from...
May 01, 2017 16:30 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML

Company’s Primary Development Focus is Non-Covalent Reversible BTK-Inhibitor SNS-062 Sunesis to Host Conference Call and Webcast in Conjunction with First Quarter 2017 Financial Results on Monday,...
April 03, 2017 08:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from an Ohio State University-sponsored preclinical study...
March 28, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President Corporate Development and...
March 22, 2017 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin

SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has submitted its responses to the European Medicine Agency (EMA)...